Current dual (SGLT2 inhibitor plus RAS inhibitor) or triple therapy [23] may be even safer than RAS monotherapy, on top of providing kidney and cardiovascular protection in different settings common in the elderly (diabetes, heart failure, CKD) and may event prevent CKD (SGLT2 inhibitors in type 2 diabetes mellitus) and heart failure [13, 23–25]. Here, SLC5A2 is linked to chronic kidney disease.